U0594

U0594 is a small‑molecule compound that has garnered interest in the pharmaceutical chemistry community for its selective inhibitory activity against protein kinase B (AKT). The chemical is a substituted indolinone derivative with the molecular formula C19H16ClNO3. Its synthesis involves a six‑step process starting from 5‑chloro‑2‑phenylbenzamide, followed by a cyclization step that introduces the indolinone core and subsequent functional group modifications to enhance potency and metabolic stability. In vitro assays reported an IC50 value of 35 nanomolar against AKT in a cell‑free kinase panel, while showing minimal off‑target activity against a panel of 150 kinases. The compound was first disclosed in a peer‑reviewed article published in the Journal of Medicinal Chemistry in 2020, where the authors showed that U0594 can reduce cell proliferation in AKT‑driven breast cancer cell lines without inducing significant cytotoxicity in normal mammary epithelial cells. Pharmacokinetic profiling in rodents indicates a half‑life of 5.6 hours and good oral bioavailability (~65%), suggesting potential for further pre‑clinical development. U0594 is currently handled under a material transfer agreement with the originating research institution and is not yet approved for clinical use.